Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Johnson and Johnson
Mallinckrodt
Baxter
Harvard Business School
Chubb
US Department of Justice
McKinsey
Medtronic
Chinese Patent Office

Generated: October 21, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,667,794

« Back to Dashboard

Claims for Patent: 5,667,794

Title: Heartburn treatment
Abstract:A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg. A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg, and an antacid. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.
Inventor(s): Simon; Thomas (Berwyn, PA), Berlin; Roger (Haverford, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/710,078
Patent Claims: 1. A method for treating a human suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg sufficient to treat heartburn, wherein the composition does not contain an antacid.

2. A method of claim 1, wherein the amount of famotidine is about 5 mg.

3. A method of claim 1, wherein the amount of famotidine is about 10 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Baxter
Harvard Business School
AstraZeneca
Daiichi Sankyo
Farmers Insurance
Argus Health
Moodys
Colorcon
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot